Biogen Inc (BIIB)

TradeGate
Currency in EUR
113.15
-1.50(-1.31%)
Closed·
BIIB is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
113.00114.85
52 wk Range
98.78219.70
Key Statistics
Edit
Bid/Ask
112.80 / 113.45
Prev. Close
114.65
Open
113.75
Day's Range
113-114.85
52 wk Range
98.78-219.7
Volume
797
Average Volume (3m)
956
1-Year Change
-45.95%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
BIIB Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Currently not supported.

Biogen Inc News & Analysis

Show more

Biogen Inc Company Profile

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS; and TOFIDENCE, a tocilizumab biosimilar referencing ACTEMRA. It offers RITUXAN to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, and biosimilars. Biogen Inc. has collaboration and license agreements with Merz Therapeutics; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; and Sage Therapeutics, Inc., as well as collaborations with Fujirebio to identify and develop biomarkers for tau pathology in the brain and Stoke Therapeutics, Inc. for the development and commercialization of zorevunersen, a disease modifying medicine for the treatment of Dravet syndrome. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Compare BIIB to Peers and Sector

Metrics to compare
BIIB
Peers
Sector
Relationship
P/E Ratio
0.0x−3.1x−0.5x
PEG Ratio
0.000.010.00
Price/Book
0.0x1.8x2.6x
Price / LTM Sales
0.0x3.4x3.1x
Upside (Analyst Target)
0.0%102.6%50.4%
Fair Value Upside
Unlock−6.3%8.7%Unlock

Earnings

Latest Release
-
EPS / Forecast
-- / --
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

BIIB Income Statement

People Also Watch

96.96
COP
+2.40%
100.00
UPS
-0.91%
130.85
PEP
-1.10%
67.31
EL
-3.83%
74.62
GPN
-4.68%

FAQ

What Is the Biogen Inc (BIIB) Stock Price Today?

The Biogen Inc stock price today is 113.15

What Stock Exchange Does Biogen Inc Trade On?

Biogen Inc is listed and trades on the Frankfurt Stock Exchange stock exchange.

What Is the Stock Symbol for Biogen Inc?

The stock symbol for Biogen Inc is "BIIB."

What Is the Biogen Inc Market Cap?

As of today, Biogen Inc market cap is 16.56B.

What Is Biogen Inc's Earnings Per Share (TTM)?

The Biogen Inc EPS (TTM) is 0.00.

From a Technical Analysis Perspective, Is BIIB a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Biogen Inc Stock Split?

Biogen Inc has split 0 times.

What is the current trading status of Biogen Inc (BIIB)?

As of 13 June 2025, Biogen Inc (BIIB) is trading at a price of 113.15, with a previous close of 114.65. The stock has fluctuated within a day range of 113.00 to 114.85, while its 52-week range spans from 98.78 to 219.70.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.